Navigation Links
ALS Patients and Researchers Unite in Boston for 4th Annual Leadership Summit
Date:9/24/2008

Panel of ALS Researchers to Present and Consider the Latest Therapeutic Approaches

CAMBRIDGE, Mass., Sept. 24 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced the line-up for its upcoming, annual ALS research symposium, part of the fourth annual ALS TDI Leadership Summit. The symposium will take place this October 20th at the Beacon Hill Holiday Inn in Boston, Mass. A diverse panel of scientists will provide presentations on the development of effective treatments, or a cure, for amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig's disease). After each presentation, audience members are invited to offer comments and ask questions regarding the research. Several of the guest speakers will participate in a panel discussion to take place between the morning and afternoon sessions. The entire event is being offered free of charge by ALS TDI.

"There is a need in the ALS community for openness and directness when it comes to describing what is done with all the monies donated for research. Providing unbiased access to information and researchers is one of the pillars of the ALS TDI philosophy. This annual event provides a unique setting for patients and researchers to connect in pursuit of a shared goal," said John McCarty, Ph.D., Director of Therapeutic Investigation at ALS TDI.

The following is a list of confirmed researchers and proposed presentation topics:

-- "Our Plan, Our Progress, Your Lab," Sean Scott, President, ALS

TDI, Cambridge, Mass.;

-- "The MDA Commitment," Sharon Hesterlee, Ph.D., Vice President

for Translational Research, Muscular Dystrophy Association, Tucson,

Ariz.;

-- "Towards defining the molecular basis of ALS: clues from

TDP-43," Michael J. Strong, M.D., Co-Chair, Department of Clinical

Neurological Sciences, Arthur J. Hudson Chair in ALS Research, London

Health Sciences Centre, London, Ontario, Canada;

-- "Development of an immunotherapy for ALS," Jean-Pierre Julien,

Ph.D., Professor, Laval University, Quebec, Quebec City, Canada;

-- "Developing an Aptamer Library for ALS," G. Thomas

Caltagirone, Ph.D., President & CEO, Aptagen, LLC, Jacobus, Penn.;

-- "A Comprehensive Approach to Communication Systems for ALS Patients

and their Families," Troy Jurgenson, Co-Founder, Speak Up ALS,

Corona del Mar, Calif.;

-- "The Genomic and Proteomic Approach to ALS Research," Steve

Perrin, Ph.D., Chief Scientific Officer, ALS TDI;

-- "Information Resources for ALS Patients and Researchers," John

McCarty, Ph.D., Director of Therapeutic Investigation, ALS TDI;

-- "The Role of Inflammation in ALS," Stan Appel, M.D.,

Co-Founder & Co-Director, Methodist Neurological Institute, Houston,

Texas.

The ALS TDI Leadership Summit is a two-day event aimed at providing a forum for the exploration of the past, present and future of research into an effective treatment for ALS. The event is designed to provide a forum for open discussions between researchers, patients and their families. The first day of the event consists of guided tours of the 16,000 square-foot translational research facility in Cambridge, Mass., where the bulk of the Institute's research team is located. There are 30 scientists and technicians that work full-time at the Institute, the largest of its kind, focused exclusively on developing an effective treatment and cure for ALS. This event is made possible in part through a fundraising partnership between ALS TDI, MDA, and its Augie's Quest initiative. The historic, three-year, $36 million funding agreement began at the start of 2007 and has played an intricate role in the expansion and acceleration of research efforts at ALS TDI and elsewhere.

The Research Symposium takes place between 8:00am and 5:00pm at the Beacon Hill Holiday Inn, and will be followed by a dinner hosted by the scientific staff of ALS TDI. At the end of the Summit, four awards will be presented to members of the ALS community that have contributed in significant ways to furthering ALS research and being advocates in their community. To attend this free day-long event, pre-registration is available online at http://www.als.net/summit or by calling Vanessa Plant at 617-441-7230.

About the ALS Therapy Development Institute

The ALS Therapy Development Institute (ALS TDI) (http://www.als.net), based in Cambridge, Mass., operates the world's largest research and development program focused exclusively on ALS. The Institute has a staff of more than 30 scientists and research technicians, working on behalf of ALS patients to discover and advance novel therapeutics for treating, and ultimately curing, ALS. The nonprofit biotechnology institute excels in identifying novel disease targets, discovering compounds that may act against these targets, and screening potential treatments for clinical development.

About Augie's Quest

Fitness pioneer Augie Nieto started Augie's Quest (http://www.augiesquest.org) in conjunction with MDA's ALS Division. Nieto is co-founder and former president of Life Fitness of Chicago, and chairman of Octane Fitness. He and his wife, Lynne, serve as co-chairpersons of MDA's ALS Division. Nieto received a diagnosis of ALS in March 2005.

About MDA

MDA (http://www.mda.org) is the world's largest provider of ALS services and funder of ALS research. Over the years, it has expended $230 million in this effort. It operated 225 clinics across the county, 38 of which are ALS-specific research and care centers.

Media Contact: Robert Goldstein, ALS TDI, 617.441.7295, rgoldstein@als.net


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ovarian and Endometrial Cancer Patients Experience Improved Outcomes When Treated First by a Gynecologic Oncologist
2. Hormone Therapy Not Best for Older Prostate Cancer Patients
3. Whole brain radiation increases risk of learning and memory problems in cancer patients
4. Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
5. Book Proceeds Help Cancer Patients at Phoenix Childrens Hospital
6. Strategies for preventing gastrointestinal complications in severely burned patients
7. The prevalence of hepatitis B virus infection in inflammatory bowel disease patients
8. How to treat gastroesophageal adenocarcinom patients?
9. SpectraScience Delivers Cancer Diagnosis System to Mayo Clinic and UCSD/VA for Detecting Esophageal Dysplasia in Patients
10. Web Site Helps Cancer Patients With Fertility Preservation
11. Girling Health Care Employees and Patients Urged to Call for Instructions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... An educational ... by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also ... advocates, associations and industry leaders such as Bioness. , As patients feel ...
(Date:5/27/2016)... ... 2016 , ... Aimed at nurses and employees in the health care world, ... in the nursing and health care industry. It also provides insight to the developing ... , As the nursing industry is coming out of one of the biggest ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to ... Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of ... grilling is their favorite way to cook a hot dog, far outpacing other cooking ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... (IP) to its specialty academic programs. , Answering to the increasing demand for ... programs in health law, and environmental and land use law. ,  , “The ...
(Date:5/26/2016)... Pittsburgh, PA (PRWEB) , ... May 26, 2016 ... ... transplantation, and one that has a significant negative impact on long-term patient survival, ... to date. The results, published online this week in the Journal of Thoracic ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 2016 Hutchison China MediTech ... on the highly lucrative global oncology and immunology ... potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) ... strategic partners. HCM,s profitable Chinese healthcare business continues ... expect progress of the mid-to-late-stage pipeline during 2016-17 ...
(Date:5/27/2016)... , May 27, 2016 Amarantus ... focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, ... will be presenting at two upcoming investor conferences: ... 730 Third Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand ...
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
Breaking Medicine Technology: